Daiken Biomedical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	1,895	1,362	1,190	884.97
Revenue Growth (YoY)	39.10%	14.45%	34.52%	-
Cost of Revenue	689.36	506.17	376.66	271.66
Gross Profit	1,206	856.22	813.76	613.3
Selling, General & Admin	906.21	696.26	601.78	493.5
Research & Development	11.28	10.16	7.82	7.36
Operating Expenses	917.52	707.3	609.61	500.87
Operating Income	288.21	148.92	204.15	112.44
Interest Expense	-0.6	-6	-3.36	-1.18
Interest & Investment Income	32.89	28.43	2.87	0.2
Currency Exchange Gain (Loss)	7.28	-31.85	-8.39	-1.92
Other Non Operating Income (Expenses)	89.69	0.11	0.08	0.01
Pretax Income	417.48	139.6	195.35	109.54
Income Tax Expense	79.62	33.02	35	19.36
Net Income	337.87	106.58	160.35	90.17
Net Income to Common	337.87	106.58	160.35	90.17
Net Income Growth	217.01%	-33.53%	77.83%	-
Shares Outstanding (Basic)	667	439	224	155
Shares Outstanding (Diluted)	668	439	225	156
Shares Change (YoY)	52.12%	95.20%	44.34%	-
EPS (Basic)	0.51	0.24	0.72	0.58
EPS (Diluted)	0.51	0.24	0.71	0.58
EPS Growth	110.95%	-66.34%	23.14%	-
Free Cash Flow	272.21	50.5	105.21	41.58
Free Cash Flow Per Share	0.41	0.12	0.47	0.27
Dividend Per Share	0.698	0.404	0.486	0.417
Dividend Growth	72.88%	-16.87%	16.55%	-
Gross Margin	63.62%	62.85%	68.36%	69.30%
Operating Margin	15.21%	10.93%	17.15%	12.71%
Profit Margin	17.83%	7.82%	13.47%	10.19%
Free Cash Flow Margin	14.36%	3.71%	8.84%	4.70%
EBITDA	295.16	153.13	205.07	112.54
EBITDA Margin	15.57%	11.24%	17.23%	12.72%
D&A For EBITDA	6.95	4.21	0.92	0.1
EBIT	288.21	148.92	204.15	112.44
EBIT Margin	15.21%	10.93%	17.15%	12.71%
Effective Tax Rate	19.07%	23.65%	17.91%	17.68%
Advertising Expenses	450.14	380.08	383.45	329.81

Source: S&P Global Market Intelligence. Standard template. Financial Sources.